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Abstract
Purpose Ibuprofen is the drug of choice for treatment of patent ductus arteriosus (PDA). There is accumulating evidence that
current ibuprofen-dosing regimens for PDA treatment are inadequate. We aimed to propose an improved dosing regimen, based
on all current knowledge.
Methods We performed a literature search on the clinical pharmacology and effectiveness of ibuprofen. (R)- and (S)-ibuprofen
plasma concentration-time profiles of different dosing regimens were simulated using a population pharmacokinetic model and
evaluated to obtain a safe, yet likely more efficacious ibuprofen exposure.
Results The most effective intravenous ibuprofen dosing in previous clinical trials included a first dose of 20 mg kg−1 followed
by 10 mg kg−1 every 24 h. Simulations of this dosing regimen show an (S)-ibuprofen trough concentration of 43 mg L−1 is
reached at 48 h, which we assumed the target through concentration. We show that this target can be reached with a first dose of
18mg kg−1, followed by 4mg kg−1 every 12 h. After 96 h postnatal age, the dose should be increased to 5 mg kg−1 every 12 h due
tomaturation of clearance. This twice-daily dosing has the advantage over once-daily dosing that an effective trough level may be
maintained, while peak concentrations are substantially (22%) lower.
Conclusions We propose to improve intermittent ibuprofen-dosing regimens by starting with a high first dose followed by a
twice-daily maintenance dosing regimen that requires increase over time and should be continued until sufficient effect has been
achieved.
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Introduction
Patent ductus arteriosus (PDA) is a potentially very harmful
condition in the youngest preterm infants, especially in those
born before 28 weeks of gestation [1]. PDA has been associ-
ated with a range of adverse outcomes including chronic lung
disease, necrotizing enterocolitis, intraventricular hemor-
rhage, and death [2–4].
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Twenty years ago, Varvarigou et al. first reported about the
effectiveness ofCOX-2 inhibitionwith early ibuprofen treatment
forhumanpreterminfantswithPDA[5].Subsequently, ibuprofen
has been dosed and licensed as once daily on three consecutive
days at 10mg kg−1, 5 mg kg−1, and 5mg kg−1 day−1 via intrave-
nous infusion. This dosing regimen leads to closure of the ductus
arteriosus in only about 60% of patients [6–9]. Despite the large
number of studies on ibuprofen for PDA, an optimal and widely
accepted dosing regimen is still lacking. Generally, increased ef-
fectiveness has been reported using higher dosages, although the
results of reports on the same dosing regimens and comparable
cohorts areverydivergent [10–18].Untilnow,onlyDesfrereet al.
[10] performed an ibuprofen dose-finding study starting in early
neonatal life in which they found a clear difference with lower
effectiveness at lower gestational age (GA), although this has not
yet led toanadapteddosing regimen.Furthermore, three random-
izedcontrolledtrialshaveshownmoreeffectivenessfor ibuprofen
treatment compared with placebo [18], and for high versus low
ibuprofen dosage [10, 15]. Recently, a state-of-the-art meta-
analyses of randomized controlled trials comparing
pharmacotherapeutic interventions by Mitra et al. in the JAMA
came to the same conclusions, and besides found higher effec-
tiveness for oral compared to intravenous administration [19]. In
current practice, local interpretation of available evidence has led
to a large variety of dosing regimens in clinical practice [20]. To
avoid further unnecessary blood sampling in this vulnerable pop-
ulation, we aimed to study available data from literature, PK
models, and simulation to suggest improved ibuprofen doses.
In the absence of sufficient evidence, the approach for an
optimized ibuprofen therapy should take into account the
physiological mechanism that causes active ductal constric-
tion. After term delivery, reduced prostaglandin E2 (PGE2)
levels are sensed by the PGE2 receptors (EP4) and promote
further constriction of the ductus. Consequently, it is assumed
that closure of a patent ductus arteriosus can be enhanced
pharmacologically. Inhibition of cyclooxygenase-2 (COX-2)
reduces PGE2 generation from arachidonic acid. Intravenous
ibuprofen is commercially available as a racemic mixture of
(R)- and (S)-ibuprofen. The (S)-enantiomer acts through com-
petition for COX-2, followed by a reversible binding and in-
hibition. (R)-ibuprofen is a relatively weak inhibitor of COX-
2 [21]. The metabolism of ibuprofen has been shown to ma-
ture during early life [12, 22], with CYP2C8 mainly respon-
sible for the metabolism of (S)-ibuprofen, and CYP2C9 for
(R)-ibuprofen. The mean half-lives for (S)- and (R)-ibuprofen
in preterm infants of about 34 h and 8 h at birth, respectively
[23], followed by a very rapid increase of (R)-ibuprofen elim-
ination during the first days of life. Furthermore, a spontane-
ous unidirectional inversion has been described of 63% of (R)-
into (S)-ibuprofen in the human body [24]. For durable effect,
the (S)-ibuprofen concentration at the COX-2 receptor should
remain above a minimal effective concentration [25]. This is
confirmed by an increased effectiveness of continuous versus
intermittent treatment [13], which has also been reported for
oral versus intravenous administration [9, 11, 26, 27]. It seems
therefore of relevance to identify a target trough concentration
for ductal closure, taking gestational and postnatal age into
account. Further, peak concentrations should be minimized
regarding safety and toxicity [28, 29]. Namely, the risk of
developing side effects and toxicity of nonsteroidal anti-
inflammatory drugs seems related to peak concentrations, as
continuous administration of indomethacin showed less side
effects than an intermittent regimen [29]. In addition, the
meta-analyses by Mitra et al. 2018 found that a continuous
infusion of intravenous ibuprofen was associated with the
lowest incidence of oliguria compared to all included intermit-
tent dosing regimens [19].
Furthermore, the high remaining proportion of patent open
ducts after 3 days of ibuprofen treatment proves that inhibitory
(S)-ibuprofen concentration was too low or treatment was too
short. Yet, if ibuprofen treatment is continued, large differ-
ences exist between neonatal intensive care units (NICUs)
on whether to use the same dosage or to increase ibuprofen
dosing with age, so to adjust for the increasing ibuprofen
clearance due to maturation.
In this study, we combine evidence on the effect of various
intravenous ibuprofen-dosing regimens on PDA closure, with
a previously developed population PK model. Additionally,
we suggest an improved ibuprofen-dosing regimen.
Methods
Effectiveness of ibuprofen
Considering ibuprofen’s mechanism of action with competi-
tive, reversible COX-2 binding [25], we aim to maintain a
minimal (S)-ibuprofen concentration for optimal effective-
ness. In this simulation study, a target trough concentration
(S)-ibuprofen was determined from simulations of (R)- and
(S)-ibuprofen plasma concentration-time profiles following
the most effective reported intravenous dosing regimen. The
latter has been recently reported in a state-of-the-art meta-
analyses by Mitra et al. in the JAMA incorporating all report-
ed pharmacotherapeutic interventions for PDA closure.
Pharmacokinetic model
Published population pharmacokinetic (PK) models of ibu-
profen in preterm infants were investigated using PubMed
with MeSH terms: BIbuprofen,^ Bpharmacokinetics,^ and
Binfant newborn^. The population PK models (see
Supplementary File 1) were compared with respect to birth
weight, gestational age (GA), and postnatal age (PNA) of
the cohort, ibuprofen-dosing regimen, route of administration,
and studied ibuprofen enantiomers [12, 22, 23, 30, 31].
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Simulations
In order to illustrate our suggestions for dosage improve-
ments, we simulated plasma concentration-time profiles of
(R)- and (S)-ibuprofen after several intravenous dosing regi-
mens for a typical neonate with PDA and a body weight of
840 g, which we determined from the cohort of all preterm
newborns with a significant PDA of the Erasmus Medical
Center [32]. First ibuprofen dosage was administered at
PNA of 24 h as an early start has shown to be more effective
than a late start.
Simulations were performed using Nonlinear Mixed
Effects Modeling (NONMEM, version 7.3, Globomax LLC,
Ellicott City, Maryland, USA) based on Gregoire et al. [23].
For simulation of intermittent dosing regimens, ibuprofen was
administered intravenously in 15 min. Higher infusion rates
would not be recommended to avoid high peak levels and
fluid overload.
We compared the population predicted trough plasma con-
centrations of (S)-ibuprofen at 48 h after start of different
dosing regimen, which concerned frequently reported regi-
mens as well as new dosing proposals. Furthermore, we com-
pared the peak concentrations as these may be related to safety
and toxicity [28, 29]. For the purpose of predicting a peak
concentration, a time point at 48.5 h after start of ibuprofen
therapy was chosen, as this was the latest dose that was ad-
ministered in 15 min at 48 h in all regimens, incorporating
15 min after infusion to allow drug distribution.
Results
Effectiveness of ibuprofen
The most effective intravenous ibuprofen-dosing regimen de-
termined in meta-analyses by Mitra et al. consisted of a
20 mg kg−1 first dose, followed by additional 10 mg kg−1
doses after 24 and 48 h, all with 15 min infusion rates [19].
Simulation of concentration-time profiles of both ibuprofen
enantiomers in a typical neonate with PDA at PNA of 24 h
and a body weight of 840 g following this dosage regimen,
predicted a corresponding (S)-ibuprofen trough concentration
at 48 h after ibuprofen start of 43 mg l−1 (Fig. 1a). Thus, for
this neonate, we hypothesized in our study that an (S)-ibupro-
fen target concentration of 43 mg l−1 will achieve optimal
effectiveness for a preterm infant with a body weight of
840 g starting ibuprofen at 24 h PNA.
Pharmacokinetic model
From the five reported population PK models on ibuprofen in
preterm born infants (see Supplementary File 2), the model by
Gregoire et al. [23] was selected, as the model was based on
the largest, and best matching cohort: 108 premature infants,
with a median birth weight of 880 g (range 300–1700), medi-
an GA of 26.9 weeks (range 24.0–30.7), median PNA of 1 day
at ibuprofen start (range 0–8), and described the PK of (R)-
and (S)-ibuprofen adequately for intravenous ibuprofen ad-
ministration of 5 to 10 mg kg−1 day−1. Their model consisted
of a one-compartment model for both (R)- and (S)-ibuprofen,
with unidirectional bioconversion of (R)-ibuprofen into (S)-
ibuprofen, and the effect of increasing elimination of the (R)-
enantiomer with increasing PNA, being the single covariate in
the model. The pharmacokinetic parameter estimates are
shown in Supplementary File 3.
Simulations
Population predictions of plasma concentration-time profiles of
(R)- and (S)-ibuprofen for a neonate at PNA 24 h and body
weight of 840 g are shown in Fig. 1 for several dosages. Table
1 gives an overview of the simulation results following different
dosing regimen. This illustration allowed to compare the dosing
regimenwith respect to the total dose of ibuprofen administered,
Cmin, Cmax. Comparison of Fig. 1b with Fig. 1c visualizes that
dividing an equal daily dose of 5mg kg−1 day−1 from one to two
administrations, increased the trough concentration from 21 to
25 mg l−1 at 48 h after start, and lowered the peak concentration
from 34 to 31 mg l−1. The determined target concentration of
43 mg l−1 for (S)-ibuprofen was reached with a first dose of
18 mg kg−1, followed by 4 mg kg−1 every 12 h
(8 mg kg−1 day−1) (Fig. 1d). Table 1 and Fig. 1 allow a compar-
ison of our most optimal simulated dosing with the most effec-
tive reported regimen of 20-10-10 as is known from previous
clinical trials. We show that comparable trough concentrations
were reached with a 5% lower cumulative 3-day dosing, and
22% lower peak concentrations. To reach the same target (S)-
ibuprofen concentration with continuous infusion, a first dose of
14 mg kg−1 fol lowed by a maintenance dose of
6.5 mg kg−1 day−1 was required (Fig. 1e). This regimen led to
the lowest total 3-day dose, and the lowest peak concentration.
Simulations upon dosing ibuprofen in neonates with a PNA of
96 h using the racemic-ibuprofen PK model of Hirt et al.
showed that an increased maintenance dosage was required to
5 mg kg−1 every 12 h (10 mg kg−1 day−1) (Fig. 1f). These
simulations illustrate our proposal to start with a first dose
followed by a maintenance dose in twice daily that requires
increased dosing over time, and should be continued until suf-
ficient effect has been achieved or treatment needs to be termi-
nated for other reasons.
Discussion
Based on reported effectiveness of ibuprofen and its mecha-
nism of action, we suggest a first loading dose followed by a
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relatively high intravenous dosage, in twice daily, which is
further increased with postnatal age, and continued until duc-
tal closure has been achieved. In our simulation study that
needs further validation first, we illustrate a dosage proposal
for an intravenous ibuprofen-dosing regimen for a typical ne-
onate with PDAwith birth weight 840 g at PNA 24 h, to start
with a first dose of 18 mg kg−1, followed by 4 mg kg−1 every
12 h. Above 96 h, the dose should be increased to 5 mg kg−1
every 12 h until sufficient effect has been achieved or treat-
ment needs to be terminated due to side effects,
contraindications, or insufficient effect. Thus, COX-2 may
be sufficiently inhibited, without exposing preterm infants to
unnecessarily high concentrations.
We combined all available evidence on the effectiveness of
intravenous ibuprofen-dosing regimens on PDA closure and
on the mechanism of action, with a previously developed (R)/
(S)-ibuprofen population pharmacokinetic model [23].
Herewith, we are the first in proposing to maintain a certain
(S)-ibuprofen target concentration. Although, the height of the
target is most certainly different with gestational and postnatal
a b c
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Fig. 1 Simulations on population-predicted plasma concentration-time
profile of (R)- and (S)-ibuprofen. Population predictions without inter-
patient variability were performed for one typical neonate with a body
weight of 840 g. A gray reference line indicates the (S)-ibuprofen target
concentration. In Figs. a–e: Plasma concentrations of the separate (R)-
and (S)-enantiomers were simulated with the PK model of Gregoire et al.
[23] starting at a postnatal age of 24 h. In Fig. f: Plasma concentrations of
racemic ibuprofen ((R) and (S) not separately) were simulated with the
PK model of Hirt et al. [12] starting at a postnatal age of 96 h.
Abbreviation: MD maintenance dose
Table 1 Population predicted (S)-ibuprofen concentrations following simulation of various intravenous ibuprofen-dosing regimens
First dose
(mg kg−1)
MD
(mg kg−1)
Duration
(days)
Cumulative dose
(mg kg−1)
Pop pred Ctrough T48 after start
(mg l−1)
Pop pred Cpeak T48.5 after start
(mg l−1)
a 20 10 every 24 h 3 40 42.5 70.4
b 10 5 every 24 h 3 20 22.2 35.2
c 10 2.5 every 12 h 3 22.5# 26.5 32.9
d 18 4 every 12 h 3 38 # 43.8 54.9
e 14 6.5 continuously 3 27 40.9 41.4
Simulations for a typical neonate with PDAwith body weight 840 g, and PNA of 24 h
#On day 1, the first dose was followed by the first maintenance dose at 12 h
MD maintenance dose, Pop pred population predictions, T time after start of ibuprofen therapy
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age, our approach is supported by the reported in vitro inhib-
itory (S)-ibuprofen concentration for COX-2 inhibition lead-
ing to 90% reduction of the agonistic effect of PGE2 (IC90)
[30, 33, 34]. Only the unbound (S)-ibuprofen concentration is
able to have an effect on the ductus arteriosus. Aranda et al.
found > 99% protein binding of (S)-ibuprofen in adult blood
compared to 94% in neonates [30]. Neupert et al. found an
IC90 for unbound (S)-ibuprofen of 2.1 mg l
−1 [34]. Assuming
an unbound fraction of 6%, a total (S)-ibuprofen concentration
of around 35 mg l−1 will achieve the IC90 for COX-2 inhibi-
tion. This finding is in line with our proposed target plasma
concentration for (S)-ibuprofen of 43 mg l−1.
We propose to divide the daily dose from one to two ad-
ministrations, either for safety or to increase effectiveness. The
risk of developing side effects and toxicity of nonsteroidal
anti-inflammatory drugs seems related to peak concentrations.
The meta-analyses by Mitra et al. reported less side effects
with a continuous administration than an intermittent regimen,
although the odds ratio for oliguria of 0.07 was not found
significant (0.00–1.84) [19]. Gournay et al. reported a placebo
controlled trial with major side effects of ibuprofen
concerning gastrointestinal adverse effects, severe intraven-
tricular hemorrhages caused by thrombocytopathy, necrotiz-
ing enterocolitis, and renal dysfunction [18]. The former has
also been illustrated by De Cock et al. [35] reporting a 16%
reduced clearance of the renally eliminated amikacin due to
combination with ibuprofen. Our proposed maintenance dos-
age of 4 mg kg−1 every 12 h, leads to comparable trough
concentrations with 10 mg kg−1 day−1 every 24 h, but with
22% lower peak concentrations. Secondly, continuous ibupro-
fen administration has been shown to be more effective than
intermittent by Lago et al. [13] even without a loading dose,
leading to 84 vs 64% PDA closure, respectively. The higher
responsiveness following a more stable ibuprofen exposure is
confirmed by the counterintuitive finding of higher closure
rates following oral than intravenous administration, which
is thought to be caused by the more graduate absorption fol-
lowing oral intake [36]. The meta-analyses byMitra et al. also
concluded that oral administration is the most effective treat-
ment, followed by high-dose intermittent IV dosing regimen
[19]. Nevertheless, oral administration is often not tolerated
during the first postnatal days of an extremely preterm born
infant. Continuous ibuprofen showed low effectiveness in the
meta-analyses, probably due to the absence of a loading dose
and relatively low maintenance. Although an adequately
dosed continuous infusion preceded by a loading dose would
be highly effective, an intermittent regimen is preferred. A
continuous infusion has multiple limitations, e.g., requiring a
continuously available intravenous catheter, physiochemical
incompatibility with intravenous co-medication, and in-
creased risk for infections. Altogether, for an intermittent reg-
imen we propose to divide the daily dose in two administra-
tions which allows to safely increase the daily dose and trough
plasma concentrations of (S)-ibuprofen with limited increase
of peak plasma concentrations.
Since Varvarigou et al. first published on ibuprofen for
PDA, most reported trials considered ibuprofen a 3-day
course, which may be repeated once or twice in clinical prac-
tice and seems to improve outcome after initial failure
[37–39]. Awaiting the result of echocardiography on day 4,
generally, no ibuprofen is administered and often will not be
restarted until the next day in case of insufficient ductal clo-
sure. This delay in ibuprofen administration leads to an unde-
sirable drop of (S)-ibuprofen plasma concentration on the
fourth day of treatment, and an unnecessary high peak con-
centration following the new loading dose with the start of an
additional 3-day course. The success of an additional course
has been shown but we considered this regimen with addition-
al 3-day courses suboptimal and potentially unsafe. Instead,
we suggest to continue ibuprofen uninterrupted, and therefore
maintain the COX-2 inhibition until sufficient closure of the
ductus arteriosus is achieved, or until ibuprofen treatment
needs to be terminated due to side effects, contraindications,
or insufficient effect. However, we were not able to propose a
reliable dosage above 96 h PNA using the PK model by
Gregoire, due to the absence of a covariate reflecting matura-
tion of clearance of (S)-ibuprofen. Namely, considering the
rapid maturation of (S)-ibuprofen’s CYP2C9 metabolism
[40], and an increased clearance is highly expected and has
been described by Hirt et al. in a cohort with median PNA of
69 h [12]. In addition to the suggested improvements follow-
ing a higher dose, considering the large interindividual vari-
ability in neonates and mechanism of action, one may also
argue that further dose tailoring, e.g., with TDM, may be of
added value. Although this off course would first require a
validated target concentration in clinical practice. Taking these
findings into account, we propose to increase the daily dosage
above a PNA of 96 h, to 5 mg kg−1 every 12 h, as this is the
highest, and still safe, investigated daily dose in preterm in-
fants (Fig. 1f).
Our approach provides important lessons and allows a
unique dose comparison, but is limited by some assumptions
we made regarding effectiveness, the target concentration, the
performance of the population PK model [23], as well as the
sparse knowledge on safety. The large variability in published
success rates may partly be caused by maturation; i.e., in-
creased spontaneous closure of the ductus with GA [41], or
increased ibuprofen clearance with GA and PNA leading to
more subtherapeutic concentrations [10, 12]. In confirmation,
Desfrere et al. reported 77% ductal closure following a first
dose of 10 mg kg−1 followed by 5 mg kg−1 on days 2 and 3 in
patients with GA of 27–29 weeks, compared to success in
31% of neonates below 27 weeks of gestation [10]. Further,
a target for ibuprofen effectiveness on PDA closure has not yet
been determined in clinical trials. If such a target would be
available, we would suggest therapeutic drug monitoring in
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the individual patient. Our simulated dosages would be a good
starting point, with further dose adaptations in the individual
patient based on bed-side determined plasma levels in the near
future. Although we considered the PK model by Gregoire et
al. as the best model available for simulations at PNA of 24 h,
the model does not scale (S)-ibuprofen PK on bodyweight nor
does it incorporate GA and PNA as a covariate for (S)-ibupro-
fen. Neither does the model allow simulations following oral
administration of ibuprofen, which has been reported with
remarkably higher effectiveness compared to intravenous dos-
ing regimens; 83% versus 62%, respectively [14, 27].
Although, oral administration to an extremely preterm born
infant is not possible on day 1 after birth due to feeding intol-
erance, it seems an attractive alternative route of administra-
tion. Furthermore, we assumed that the ibuprofen PK is linear
over a 5–20 mg kg−1 dose range, while linearity has only been
explored within the 5–10 mg kg−1 range for model develop-
ment. As such, we could not simulate beyond 96 h PNAwith
the PK model of Gregiore. Finally, safety has not yet been
related to ibuprofen dosage and exposure.
Concluding, currently used ibuprofen-dosing regimens
for PDA seem suboptimal. Based on the best evidence
thus far available, we suggest that if decided to treat the
PDA intravenously, a high dosage should be used in twice
daily, increased with postnatal age, and continued until
ductal closure has been achieved. For illustration, a typical
neonate with birth weight 840 g at PNA 24 h may start
with an ibuprofen first dose of 18 mg kg−1, followed by a
maintenance dose of 4 mg kg−1 every 12 h until 96 h
PNA. Above 96 h, a dose increase is suggested to
5 mg kg−1 per dose every 12 h until sufficient effect has
been achieved or treatment needs to be terminated due to
side effects, contraindications, or insufficient effect.
Thereby, sufficient inhibition of COX-2 may be achieved
and maintained, without exposing preterm infants to un-
necessarily high (S)-ibuprofen peak concentrations that
have not been proven safe. These suggestions should be
incorporated in current ibuprofen dosing regimens and re-
quire a prospective evaluation, allowing to bridge the re-
maining gaps concerning treatment outcome of different
administration routes, maturation of spontaneous closure,
safety of ibuprofen dosing regimens, and covariates for
(S)-ibuprofen PK. Finally, placebo controlled studies are
warranted to characterize dynamics of natural PDA closure
and to quantify drug-related effectiveness.
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